{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T19:59:04Z","timestamp":1776628744802,"version":"3.51.2"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:p>Hepatogenous diabetes (HD) is a glycogen metabolism disorder that arises as a consequence of chronic liver disease. The condition is frequently detected in patients diagnosed with cirrhosis, which is a result of advanced liver disease. The prognosis for patients with HD is generally poor, and they are at a heightened risk for serious complications such as gastrointestinal bleeding, primary peritonitis, and hepatic encephalopathy. Hepatogenous diabetes progression is often associated with cirrhosis progression, which leads to the development of liver cancer and increased patient mortality. Despite the prevalence and severity of HD, no systematic treatment strategy for clinical management of the condition has been proposed by any research or institutions to date. This paper conducts an extensive review of recent advancements in HD treatment in the quest for an effective treatment approach that may improve the overall prognosis of HD.<\/jats:p>","DOI":"10.1097\/md.0000000000036068","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T09:21:30Z","timestamp":1701163290000},"page":"e36068","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Advances in the treatment of hepatogenous diabetes: A review"],"prefix":"10.1097","volume":"102","author":[{"given":"Yanru","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Clinical Nutrition, West China Hospital; Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyu","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, Department of General Surgery, West China Hospital; Sichuan University, Chengdu, Sichuan Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, Department of General Surgery, West China Hospital; Sichuan University, Chengdu, Sichuan Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WeiMing","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, Department of General Surgery, West China Hospital; Sichuan University, Chengdu, Sichuan Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-437X","authenticated-orcid":false,"given":"Wen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, West China Hospital; Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/emm.2015.122","article-title":"Regulation of glucose metabolism from a liver-centric perspective.","volume":"48","author":"Han","year":"2016","journal-title":"Exp Mol Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e00416","DOI":"10.1042\/BSR20160385","article-title":"Liver glucose metabolism in humans.","volume":"36","author":"Adeva-Andany","year":"2016","journal-title":"Biosci Rep"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.13337","article-title":"Hepatogenous diabetes: is it time to separate it from type 2 diabetes?","volume":"37","author":"Orsi","year":"2017","journal-title":"Liver Int"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1440-1746.2002.02755.x","article-title":"Clinical implications of hepatogenous diabetes in liver cirrhosis.","volume":"17","author":"Holstein","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases.","volume":"56","author":"Bechmann","year":"2012","journal-title":"J Hepatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jcm10020262","article-title":"Association between liver cirrhosis and diabetes mellitus: a review on hepatic outcomes.","volume":"10","author":"Coman","year":"2021","journal-title":"J Clin Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.","volume":"15","author":"Garcia-Compean","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R8-20250504","first-page":"1158","article-title":"Recent developments in the diagnosis of hepatogenous diabetes.","volume":"24","author":"Tian","year":"2021","journal-title":"Chinese General Pract"},{"key":"R9-20250504","first-page":"524","article-title":"Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2.","volume":"12","author":"Kim","year":"2006","journal-title":"Korean J Hepatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diabres.2015.10.002","article-title":"Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant.","volume":"110","author":"Ramos-Prol","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4254\/wjh.v14.i7.1291","article-title":"Hepatogenous diabetes: knowledge, evidence, and skepticism.","volume":"14","author":"Kumar","year":"2022","journal-title":"World J Hepatol"},{"issue":"Supplement_2","key":"R12-20250504","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.2337\/dc08-s264","article-title":"Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?","volume":"31","author":"Shanik","year":"2008","journal-title":"Diabetes Care"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00535-013-0893-z","article-title":"Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension.","volume":"49","author":"Ishikawa","year":"2014","journal-title":"J Gastroenterol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jhep.2015.08.011","article-title":"Contribution of \u03b2-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.","volume":"63","author":"Grancini","year":"2015","journal-title":"J Hepatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"E710","DOI":"10.1152\/ajpendo.00052.2019","article-title":"Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2\u03b1\/PPAR\u03b1 pathway.","volume":"317","author":"Chen","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R16-20250504","first-page":"1","article-title":"Hepatitis B and C virus infection and diabetes mellitus: a cohort study.","volume":"7","author":"Hong","year":"2017","journal-title":"Sci Rep"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-015-0241-4","article-title":"Inhibition of IRS-1 by hepatitis C virus infection leads to insulin resistance in a PTEN-dependent manner.","volume":"12","author":"Gao","year":"2015","journal-title":"Virol J"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"11887","DOI":"10.1074\/jbc.M409475200","article-title":"The islet \u03b2 cell-enriched MafA activator is a key regulator of insulin gene transcription.","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1017\/S0007114509993060","article-title":"Insulin release, peripheral insulin resistance and muscle function in protein malnutrition: a role of tricarboxylic acid cycle anaplerosis.","volume":"103","author":"Zoppi","year":"2010","journal-title":"Br J Nutr"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clinre.2017.09.005","article-title":"Physical exercise in cirrhotic patients: towards prehabilitation on waiting list for liver transplantation A systematic review and meta-analysis.","volume":"42","author":"Brustia","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1249\/MSS.0000000000002800","article-title":"Exercise\/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine.","volume":"54","author":"Kanaley","year":"2022","journal-title":"Med Sci Sports Exerc"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4103\/ijem.IJEM_79_18","article-title":"Hepatogenous diabetes: an underestimated problem of liver cirrhosis.","volume":"22","author":"Kumar","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"R23-20250504","first-page":"1979","article-title":"Glycated hemoglobin and fructosamine level in complicated and non-complicated chronic alcoholic liver disease.","volume":"12","author":"Soni","year":"2022","journal-title":"Natl J Physiol Pharmacy Pharmacol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ajg.2018.08.003","article-title":"Managing diabetes and liver disease association.","volume":"19","author":"Elsahar","year":"2018","journal-title":"Arab J Gastroenterol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes.","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet (London, England)"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes.","volume":"5","author":"Aguayo Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"R27-20250504","first-page":"389","article-title":"The role of AMP kinase in diabetes.","volume":"125","author":"Misra","year":"2007","journal-title":"Indian J Med Res"},{"key":"R28-20250504","first-page":"348","article-title":"Cancer towards diabetes treatment: the suppressor of tumor LKB1 as a new pharmacological target.","volume":"22","author":"Foretz","year":"2006","journal-title":"Med Sci"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral Hepatitis C in diabetic patients.","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-20250504","first-page":"277","article-title":"Oral glutamine challenge improves the performance of psychometric tests for the diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis.","volume":"22","author":"Irimia","year":"2013","journal-title":"J GastrointestinLiver Dis"},{"key":"R31-20250504","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/archinte.163.21.2594","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus - Systematic review and meta-analysis.","volume":"163","author":"Salpeter","year":"2003","journal-title":"Arch Intern Med"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.13160","article-title":"Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis.","volume":"20","author":"McGovern","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/dc06-1539","article-title":"Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease.","volume":"30","author":"Tolman","year":"2007","journal-title":"Diabetes Care"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of diabetes mellitus in patients with CKD: Core curriculum 2022.","volume":"79","author":"Hahr","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/dom.12101","article-title":"Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?","volume":"15","author":"Consoli","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.diabres.2006.08.017","article-title":"Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan.","volume":"76","author":"Kawamori","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: AMeta-analysis.","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study The Pioglitazone 001 Study Group.","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1517\/14656566.2015.1070827","article-title":"Therapeutic potential of alpha-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1542-3565(04)00667-6","article-title":"A randomized controlled trial of acarbose in hepatic encephalopathy.","volume":"3","author":"Gentile","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1463-1326.2001.00103.x","article-title":"Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.","volume":"3","author":"Gentile","year":"2001","journal-title":"Diabetes Obesity Metabol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1G336","article-title":"Hepatotoxicity associated with acarbose therapy.","volume":"40","author":"Hsiao","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2165\/00003495-200059030-00012","article-title":"Miglitol - A review of its therapeutic potential in type 2 diabetes mellitus.","volume":"59","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes.","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ene.13905","article-title":"Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.","volume":"26","author":"Barkas","year":"2019","journal-title":"Eur J Neurol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.endoen.2016.05.008","article-title":"Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: an observational, pilot study.","volume":"63","author":"D\u00edaz","year":"2016","journal-title":"Endocrinol Nutr (English Edition)"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","article-title":"Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.","volume":"70","author":"Flint","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art.","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/cas.12203","article-title":"Report of the Japan Diabetes Society\/Japanese Cancer Association joint committee on diabetes and cancer.","volume":"104","author":"Kasuga","year":"2013","journal-title":"Cancer Sci"},{"key":"R54-20250504","first-page":"18","article-title":"Cancer: Repurposing SGLT2 inhibitors.","volume":"18","author":"Crunkhorn","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27228","article-title":"Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C.","volume":"60","author":"Elkrief","year":"2014","journal-title":"Hepatology"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci Rep"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus In: Caskey CT, ed.","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.numecd.2016.02.015","article-title":"Frequency and characteristics of diabetes in 300 pre-liver transplant patients.","volume":"26","author":"Marselli","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40265-015-0500-0","article-title":"Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience.","volume":"76","author":"Hermansen","year":"2016","journal-title":"Drugs"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-021-00690-0","article-title":"Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes.","volume":"21","author":"Yen","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2019.1653184","article-title":"HCV treatment with direct acting antivirals improves the insulin sensitivity.","volume":"17","author":"Alsebaey","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"R63-20250504","first-page":"1330","article-title":"Effects of entecavir on liver fibrosis indices in patients with hepatogenous diabetes.","volume":"30","author":"Wei","year":"2014","journal-title":"J Clin Hepatol"},{"key":"R64-20250504","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/jpm13060964","article-title":"Current therapy of chronic viral Hepatitis B, C and D.","volume":"13","author":"Schlaak","year":"2023","journal-title":"J Personalized Med"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S2095-4964(14)60039-X","article-title":"Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities.","volume":"12","author":"Zhao","year":"2014","journal-title":"J Integr Med"},{"key":"R66-20250504","first-page":"775","article-title":"Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses.","volume":"36","author":"Yang","year":"2016","journal-title":"Nan Fang yi ke da xue xue bao"},{"key":"R67-20250504","doi-asserted-by":"crossref","first-page":"109128","DOI":"10.1016\/j.biopha.2019.109128","article-title":"Traditional Chinese medicine combined with hepatic targeted drug delivery systems: a new strategy for the treatment of liver diseases.","volume":"117","author":"Ma","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R68-20250504","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/00007890-200006150-00043","article-title":"Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance.","volume":"69","author":"Shetty","year":"2000","journal-title":"Transplantation"},{"key":"R69-20250504","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.2337\/dc13-0400","article-title":"Liver transplantation: a potential cure for hepatogenous diabetes?","volume":"36","author":"Pallayova","year":"2013","journal-title":"Diabetes Care"},{"key":"R70-20250504","first-page":"627","article-title":"New-Onset diabetes after transplant in a sudanese renal transplant population: prevalence and risk factors.","volume":"15","author":"Ahmed","year":"2017","journal-title":"Exp Clin Transplant"},{"key":"R71-20250504","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1253\/circj.CJ-16-0963","article-title":"New-Onset diabetes mellitus after heart transplantation - Incidence, risk factors and impact on clinical outcome.","volume":"81","author":"Kim","year":"2017","journal-title":"Circ J"},{"key":"R72-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17512433.2021.1851596","article-title":"pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression.","volume":"14","author":"Chevallier","year":"2021","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T08:03:16Z","timestamp":1746345796000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":72,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036068","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}